Clarius Group LLC Sells 994 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Clarius Group LLC reduced its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 9.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,000 shares of the biopharmaceutical company’s stock after selling 994 shares during the period. Clarius Group LLC’s holdings in Sage Therapeutics were worth $217,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. RTW Investments LP bought a new position in shares of Sage Therapeutics in the third quarter worth about $105,976,000. Goldman Sachs Group Inc. increased its position in Sage Therapeutics by 252.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 1,106,276 shares of the biopharmaceutical company’s stock worth $35,733,000 after buying an additional 792,819 shares during the period. State Street Corp lifted its holdings in shares of Sage Therapeutics by 30.8% during the first quarter. State Street Corp now owns 2,835,356 shares of the biopharmaceutical company’s stock worth $93,850,000 after buying an additional 666,826 shares during the last quarter. BlackRock Inc. boosted its position in shares of Sage Therapeutics by 13.7% in the third quarter. BlackRock Inc. now owns 4,822,063 shares of the biopharmaceutical company’s stock valued at $188,833,000 after acquiring an additional 580,250 shares during the period. Finally, Morgan Stanley grew its stake in shares of Sage Therapeutics by 145.5% in the third quarter. Morgan Stanley now owns 863,932 shares of the biopharmaceutical company’s stock worth $17,780,000 after acquiring an additional 512,021 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

SAGE has been the subject of several research analyst reports. JPMorgan Chase & Co. upped their target price on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, March 26th. Stifel Nicolaus cut their price objective on shares of Sage Therapeutics from $22.00 to $20.00 and set a “hold” rating for the company in a research report on Monday, December 18th. Royal Bank of Canada lifted their target price on Sage Therapeutics from $21.00 to $26.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 15th. Morgan Stanley upped their price target on Sage Therapeutics from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. Finally, HC Wainwright raised their price objective on Sage Therapeutics from $25.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, February 15th. Fifteen equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $41.00.

Sage Therapeutics Trading Down 0.8 %

Shares of SAGE stock opened at $15.32 on Tuesday. The firm’s 50 day moving average is $20.47 and its 200-day moving average is $21.05. Sage Therapeutics, Inc. has a 1 year low of $15.06 and a 1 year high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last released its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($1.28) by $0.73. The company had revenue of $77.97 million during the quarter, compared to analysts’ expectations of $60.15 million. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The business’s revenue for the quarter was up 2621.5% on a year-over-year basis. During the same period last year, the firm earned ($2.47) EPS. Equities research analysts anticipate that Sage Therapeutics, Inc. will post -6.05 earnings per share for the current fiscal year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.